Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2010

01-10-2010 | Original Article

Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population?

Authors: Núria Vilarrasa, Joan Vendrell, Javier Maravall, Iñaki Elío, Esther Solano, Patricia San José, Isabel García, Núria Virgili, Juan Soler, José Manuel Gómez

Published in: Endocrine | Issue 2/2010

Login to get access

Abstract

To analyse in a cohort of healthy subjects and in a group of morbidly obese patients, we studied the association amongst 25(OH) D and plasma concentrations of adipocytokines, inflammatory cytokines and insulin resistance. We also aimed to determine whether vitamin D-deficient patients showed a greater inflammatory profile. In the observational study that the authors conducted, plasma concentrations of 25(OH) D, leptin, resistin, adiponectin and interleukine-18 were determined in 134 healthy men and 127 women. In the population consisting of 44 patients with morbid obesity, plasma concentrations of 25(OH) D, leptin, resistin, adiponectin, interleukine-18, soluble tumor necrosis factor receptors 1 and 2 and C-reactive protein were analysed. In the healthy population, plasma 25(OH) D showed a negative correlation with body mass index, body fat, waist, hip circumference and with leptin. However, no significant associations were found amongst 25(OH) D and plasma concentrations of resistin, adiponectin or interleukine-18. Patients with vitamin D deficiency showed higher body mass index, fat mass percentage and higher leptin concentrations compared with subjects with normal 25(OH) D concentrations. In the morbidly obese subjects, 25(OH) D did not correlate with leptin, resistin, adiponectin, interleukine-18, soluble tumor necrosis factor receptors 1 and 2 or with C-reactive protein. In patients with morbid obesity, no differences were found in adipokines and inflammatory cytokines concentrations regarding 25(OH) D status. No associations were found either between 25(OH) D and plasma glucose and insulin resistance or with lipid profile. Plasma 25(OH) D concentrations are associated with adiposity markers but not with adipocytokines implicated in inflammation. This lack of association does not support a major role of 25(OH) D in the pro-inflammatory environment observed in morbidly obese subjects. In addition, subjects with vitamin D deficiency are not characterized by a greater inflammatory state.
Literature
1.
2.
3.
M.F. Holick, The role of vitamin D for bone health and fracture prevention. Curr. Osteoporos. Rep. 4, 96–102 (2006)CrossRefPubMed
4.
R.P. Heany, The Vitamin D requirement in health and disease. J. Steroid Biochem. Mol. Biol. 97, 13–19 (2005)CrossRef
5.
M.T. Cantorna, Y. Zhu, M. Froicu, A. Wittke, Vitamin D status, 1,25-dihidroxyvitamin D3, and the immune system. Am. J. Clin. Nutr. 80, 1717s–1720s (2004)PubMed
6.
H.F. Deluca, M.T. Cantorna, Vitamin D: its role and uses in immunology. FASEB J. 15, 2579–2585 (2001)CrossRefPubMed
7.
8.
H. Ishida, A.W. Norman, Demonstration of a high affinity receptor for 1,25-dihydroxyvitamin D3 in a rat pancreas. Mol. Cell. Endocrinol. 60, 109–117 (1988)CrossRefPubMed
9.
J.A. Johnson, J.P. Grande, P.C. Roche, R. Kumar, Immunohistochemical localization of the 1, 25 (OH)2 D3 receptor and calbindin D28k in human and rat pancreas. Am. J. Physiol. 267, E356–E360 (1994)PubMed
10.
S. Chen, G.P. Sims, X.X. Chen, Y.Y. Gu, S. Chen, P.E. Lipsky, Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 179, 1634–1647 (2007)PubMed
11.
J.M. Lemire, D.C. Archer, L. Beck, H.L. Spiegelberg, Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J. Nutr. 125, 1704S–1708S (1995)PubMed
12.
D. Mauricio, T. Mandrup-Poulsen, J. Nerup, Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Diabetes Metab. Rev. 12, 57–68 (1996)PubMed
13.
J.M. Lemire, Immunomodulatory actions of 1, 25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 53, 599–602 (1995)CrossRefPubMed
14.
L. Overbergh, B. Decallonne, D. Valckx, A. Verstuf, J. Depovere, J. Laureys, O. Rutgeerts, R. Saint-Arnaud, R. Bouillon, C. Mathieu, Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin. Exp. Immunol. 120, 139–146 (2000)CrossRefPubMed
15.
C.A. Peterson, M.E. Heffernan, Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH) D concentrations in healthy women. J. Inflamm. 5, 10–19 (2008)CrossRef
16.
S.S. Schleithoff, A. Zittermann, G. Tenderich, H.K. Berthold, P. Stehle, R. Koefer, Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 83, 754–759 (2006)PubMed
17.
S. Türk, M. Akbulut, A. Yildiz, M. Gürbilek, S. Gönen, Z. Tombol, M. Yeksan, Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 90, 188–194 (2002)CrossRefPubMed
18.
J.S. Yudkin, C.D. Stehouwer, J.J. Emeis, S.W. Coppack, C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler. Thromb. Vasc. Biol. 19, 972–978 (1999)PubMed
19.
X. Palomer, J.M. González-Clemente, F. Blanco-Vaca, D. Mauricio, Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes. Metab. 10, 185–197 (2008)CrossRefPubMed
20.
K.C. Chiu, A. Chu, V.L. Go, M.F. Saad, Hypovitaminosis D is associated with insulin resistance and β cell dysfunction. Am. J. Clin. Nutr. 79, 820–825 (2004)PubMed
21.
M.A. Pereira, D.R. Jacobs, L. Van Horn, M.L. Slattery, A.I. Kartashov, D.S. Ludwig, Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. JAMA 287, 2081–2089 (2002)CrossRefPubMed
22.
E.S. Ford, U.A. Ajani, L.C. Mc Guire, S. Liu, Concentrations of serum vitamin D and the metabolic syndrome among US adults. Diabetes Care 28, 1228–1230 (2005)CrossRefPubMed
23.
U.G. Kyle, I. Bosaeus, A.D. De Lorenzo, P. Deurenberg, M. Elia, J.M. Gómez, B. Lilienthal Heitmann, L. Kent-Smith, J.C. Melchior, M. Pirlich, H. Scharfetter, M.W.J. Schols A, C. Pichard, Bioelectrical impedance analysis, Part II: utilization in clinical practice. Clin. Nutr. 23, 1430–1453 (2004)CrossRefPubMed
24.
World Health Organization, Obesity: preventing and managing the global epidemic. Report on a WHO consultation on obesity. WHO/NUT/NCD/98.1. WHO, Geneva, 3–5 June 1997
25.
D.T. Villareal, R. Citivelli, A. Chines, L.V. Avioli, Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass. J. Clin. Endocrinol. Metab. 72, 628–634 (1991)CrossRefPubMed
26.
M.K. Thomas, D.M. Lloyd-Jones, R.I. Thadhani, A.C. Shaw, D.J. Deraska, B.T. Kitch, E.C. Vamvakas, I.M. Dick, R.L. Prince, J.S. Fikelstein, Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338, 777–783 (1998)CrossRefPubMed
27.
C. Menendez, M. Lage, R. Peino, R. Baldelli, P. Concheiro, C. Diéguez, F.F. Casanueva, Retinoid acid and vitamin D3 powerfully inhibit in vitro leptin secretion by human adipose tissue. J. Endocrinol. 170, 425–431 (2001)CrossRefPubMed
28.
C.L. McTernan, P.G. McTernan, A.L. Harte, P.L. Levick, A.H. Barnett, S. Kumar, Resistin central obesity and type 2 diabetes. Lancet 35, 46–47 (2002)CrossRef
29.
M. Filková, M. Haluzík, S. Gay, L. Senolt, The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin. Immunol. 133, 157–170 (2009)CrossRefPubMed
30.
M. Bokarewa, I. Nagaev, L. Dahlberg, U. Smith, A. Tarkowski, Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 174, 5789–5795 (2005)PubMed
31.
X. Sun, M.B. Zemel, Calcium and 1,25-dihydroxyvitamin D3 regulation of adipokine expression. Obesity 15, 340–348 (2007)CrossRefPubMed
32.
M.T. Cantorna, B.D. Mahon, D-hormone and the immune system. J. Rheumatol. 76, 11–20 (2005)
33.
E. Liu, J.B. Meigs, A.G. Pittas, N.M. Mc Keown, C.D. Economos, S.L. Booth, P.F. Jacques, Plasma 25-hydroxyvitamin D is associated with markers of the insulin resistant phenotype in nondiabetic adults. J. Nutr. 139, 329–334 (2009)PubMed
34.
M.H. Gannagé-Yared, R. Chedid, S. Khalife, E. Azzi, F. Zoghbi, G. Halaby, Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur. J. Endocrinol. 160, 965–971 (2009)CrossRefPubMed
35.
J.J. Diez, P. Iglesias, The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 148, 293–300 (2003)CrossRefPubMed
36.
A. Zittermann, S. Frisch, H.K. Berthold, C. Götting, J. Kuhn, K. Kleesiek, P. Stehle, H. Koertke, R. Koerfer, Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am. J. Clin. Nutr. 89, 1321–1327 (2009)CrossRefPubMed
37.
D. Aderka, H. Engelmann, Y. Maor, C. Brakebusch, D. Wallach, Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175, 323–329 (1992)CrossRefPubMed
38.
J.P. Bastard, C. Jardel, E. Bruckert, H. Vidal, B. Hainque, Variations in plasma soluble tumour necrosis factor receptors after diet-induced weight loss in obesity. Diabetes Obes. Metab. 2, 323–325 (2000)CrossRefPubMed
39.
B. Zahorska-Markiewicz, J. Janowska, M. Olszanecka-Glinianowicz, A. Zurakowski, Serum concentrations of TNF-α and soluble TNF-α receptors in obesity. Int. J. Obes Relat. Metab. Disord. 24, 1392–1395 (2000)CrossRefPubMed
40.
M. Olszanecka-Glinianowicz, B. Zahorska-Markiewicz, J. Janowska, The effect of weight loss on serum concentrations of nitric oxide, TNF-alpha and TNF-alpha receptors. Pol. J. Endocrinol. 57, 487–493 (2006)
41.
C.A. Dinarello, Interleukin-18: a proinflammatory cytokine. Eur. Cytokine Netw. 11, 483–486 (2000)PubMed
42.
I.B. Mc Innes, J.A. Gracie, B.P. Leung, X.Q. Wei, F.Y. Liew, Interleukin 18: a pleiotropic participant in chronic inflammation. Immunol. Today 21, 312–315 (2000)CrossRef
43.
N. Vilarrasa, J. Vendrell, R. Sanchez-Santos, M. Broch, A. Megia, C. Masdevall, N. Gomez, J. Soler, J. Pujol, C. Bettonica, H. Aanda, J.M. Gómez, Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, c-reactive protein and adiponectin in morbidly obese patients. Clin. Endocrinol. (Oxf) 67, 679–686 (2007)CrossRef
44.
N. Vilarrasa, J.M. Gómez, C. Masdevall, J. Pujol, J. Soler, I. Elio, L. Gallart, J. Vendrell, Study of the relationship between adiponectin, interleukin-18, ghrelin and bone mineral density in morbidly obese women after gastric by-pass. Endocrinol. Nutr. 56, 355–360 (2009)CrossRefPubMed
45.
Z. Mallat, A. Corbaz, A. Scoazec, S. Besnard, G. Lesèche, Y. Chvatchko, A. Tedgui, Expression of Interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104, 1598–1603 (2001)CrossRefPubMed
46.
Z. Mallat, A. Corbaz, A. Scoazec, P. Graber, S. Alouani, B. Esposito, Y. Humbert, Y. Chvatchko, A. Tedgui, Interleukin-18/interleukin-18 binding protein signalling modulates atherosclerotic lesion development and stability. Circ. Res. 89, E41–E45 (2001)CrossRefPubMed
47.
D.T. Ngo, A.L. Sverdlov, J.J. McNeil, J.D. Horowitz, Does vitamin D modulate asymmetric dimethylarginine and C-reactive protein concentrations? Am. J. Med. 123, 335–341 (2010)CrossRefPubMed
48.
R. Jorde, M. Sneve, P.A. Torjesen, Y. Figenschau, L.G. Gøransson, R. Omdal, No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine. 50, 175–180 (2010)CrossRefPubMed
49.
E.D. Michos, E.A. Streeten, K.A. Ryan, E. Rampersaud, P.A. Peyser, L.F. Bielak, A.R. Shuldiner, B.D. Mitchell, W. Post, Serum 25-hydroxyvitamin D levels are not associated with subclinical vascular disease or C-reactive protein in the old order Amish. Calcif. Tissue Int. 84, 423–424 (2009)CrossRef
50.
G. Isaia, R. Giordano, S. Adami, High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care 24, 1496 (2001)CrossRefPubMed
51.
A.G. Pittas, J. Lau, F.B. Hu, B. Dawson-Hughes, The role of vitamin d and calcium in type 2 diabetes. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 92, 2017–2029 (2007)CrossRefPubMed
52.
S.E. Shoelson, L. Herrero, A. Naaz, Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169–2180 (2007)CrossRefPubMed
53.
J.I. Botella-Carretero, F. Alvarez-Blasco, J.J. Villafruela, J.A. Balsa, C. Vázquez, H.F. Escobar-Morreale, Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin. Nutr. 26, 573–580 (2007)CrossRefPubMed
54.
S. Rueda, C. Fernández-Fernández, F. Romero, J. Martínez de Osaba, J. Vidal, Vitamin D, PTH and the metabolic syndrome in severely obese subjects. Obes. Surg. 18, 151–154 (2008)CrossRefPubMed
Metadata
Title
Is plasma 25(OH) D related to adipokines, inflammatory cytokines and insulin resistance in both a healthy and morbidly obese population?
Authors
Núria Vilarrasa
Joan Vendrell
Javier Maravall
Iñaki Elío
Esther Solano
Patricia San José
Isabel García
Núria Virgili
Juan Soler
José Manuel Gómez
Publication date
01-10-2010
Publisher
Springer US
Published in
Endocrine / Issue 2/2010
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9379-4

Other articles of this Issue 2/2010

Endocrine 2/2010 Go to the issue

Original Article

Abnormal hypothalamic oxytocin system in fibroblast growth factor 8-deficient mice

Original Article

No effect of bicarbonate treatment on insulin sensitivity and glucose control in non-diabetic older adults

Original Article

The glucose-induced synthesis of insulin in liver

Original Article

Increased ghrelin sensitivity and calorie consumption in subordinate monkeys is affected by short-term astressin B administration

Case Report and Review

Disappearing adrenal masses

Original Article

Oxidative DNA damage: the thyroid hormone-mediated effects of insulin on liver tissue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits